Trade PTC Therapeutics - PTCT CFD
Add to favourite- Summary
- Historical Data
Spread | 0.08 | ||||||||
Long position overnight fee
Long position overnight fee
Go to platform | -0.026179% | ||||||||
Short position overnight fee
Short position overnight fee
Go to platform | 0.003957% | ||||||||
Overnight fee time | 21:00 (UTC) | ||||||||
Min traded quantity | 1 | ||||||||
Currency | USD | ||||||||
Margin | 5% | ||||||||
Stock exchange | United States of America | ||||||||
Commission on trade | 0% |
Prev. Close | 25.47 |
Open | 26.15 |
1-Year Change | -48.93% |
Day's Range | 26.15 - 29.02 |
- Last Week
- Last Month
- Last Year
- Last two Years
- Max
- Daily
- Weekly
- Monthly
Date | Close | Change | Change (%) | Open | High | Low |
---|---|---|---|---|---|---|
Apr 26, 2024 | 28.54 | 3.05 | 11.97% | 25.49 | 29.21 | 25.25 |
Apr 25, 2024 | 25.47 | 1.00 | 4.09% | 24.47 | 25.59 | 23.98 |
Apr 24, 2024 | 25.16 | -0.05 | -0.20% | 25.21 | 25.89 | 24.82 |
Apr 23, 2024 | 25.34 | -0.16 | -0.63% | 25.50 | 26.18 | 25.07 |
Apr 22, 2024 | 25.92 | 0.87 | 3.47% | 25.05 | 26.44 | 25.04 |
Apr 19, 2024 | 25.29 | 0.97 | 3.99% | 24.32 | 25.50 | 24.32 |
Apr 18, 2024 | 24.67 | 0.32 | 1.31% | 24.35 | 25.16 | 24.35 |
Apr 17, 2024 | 25.12 | 0.11 | 0.44% | 25.01 | 25.39 | 24.71 |
Apr 16, 2024 | 25.22 | 0.09 | 0.36% | 25.13 | 26.29 | 25.10 |
Apr 15, 2024 | 25.64 | -0.17 | -0.66% | 25.81 | 26.56 | 25.30 |
Apr 12, 2024 | 26.40 | -0.97 | -3.54% | 27.37 | 27.89 | 26.06 |
Apr 11, 2024 | 27.35 | 0.14 | 0.51% | 27.21 | 27.46 | 26.63 |
Apr 10, 2024 | 26.83 | 0.35 | 1.32% | 26.48 | 27.10 | 26.12 |
Apr 9, 2024 | 27.54 | 1.18 | 4.48% | 26.36 | 27.68 | 26.36 |
Apr 8, 2024 | 26.84 | 0.28 | 1.05% | 26.56 | 27.31 | 26.51 |
Apr 5, 2024 | 26.95 | 0.77 | 2.94% | 26.18 | 27.65 | 26.18 |
Apr 4, 2024 | 27.75 | -0.92 | -3.21% | 28.67 | 29.18 | 27.67 |
Apr 3, 2024 | 28.93 | 0.96 | 3.43% | 27.97 | 29.11 | 27.52 |
Apr 2, 2024 | 28.33 | 0.87 | 3.17% | 27.46 | 28.89 | 27.46 |
Apr 1, 2024 | 28.53 | -0.26 | -0.90% | 28.79 | 28.79 | 27.89 |
Trading calculator
Calculate your hypothetical P&L if you had opened a CFD trade on a certain date (select a date) and closed on a different date (select a date).
- 1:1
- 20
- 100
- 500
- 1000
- 10000
PTC Therapeutics Company profile
About PTC Therapeutics, Inc.
PTC Therapeutics, Inc. is a science-driven global biopharmaceutical company. The Company is focused on the discovery, development and commercialization of clinically differentiated medicines that provide benefits to patients with rare disorders. The Company's portfolio pipeline includes several commercial products and product candidates in various stages of development, including clinical, pre-clinical and research and discovery stages, focused on the development of new treatments for multiple therapeutic areas, including rare diseases and oncology. The Company has two products, Translarna (ataluren) and Emflaza (deflazacort), for the treatment of Duchenne muscular dystrophy (DMD). It has a pipeline of gene therapy product candidates for rare monogenic diseases that affect the central nervous system (CNS), including PTC-AADC for the treatment of Aromatic L-Amino Acid Decarboxylase (AADC).
Financial summary
BRIEF: For the fiscal year ended 31 December 2021, PTC Therapeutics, Inc. revenues increased 41% to $538.6M. Net loss increased 20% to $523.9M. Revenues reflect United States segment increase of 59% to $297M, Non-US segment increase of 24% to $241.6M. Higher net loss reflects Non-GAAP research and development increase of 11% to $487.1M (expense), Interest expense, net - Balancing value increase of 52% to $85.1M (expense).
Equity composition
Common Stock $0.001 Par, Shares auth 125M., 22,206,190 shares issd,. Insiders Owns approx.68.93%
Industry: | Bio Therapeutic Drugs |
100 Corporate Ct
SOUTH PLAINFIELD
NEW JERSEY 07080-2400
US
News
We’re partnering with Newsquawk
Filter out the noise and focus on the news that matters.
08:32, 23 April 2024US Earnings Season: Tesla, Alphabet, Meta Platforms and Microsoft
The first lot of Wall Street’s mega-cap tech companies report in the coming week. We preview what to expect from Tesla, Alphabet, Meta, and Microsoft’s quarterly results.
15:56, 22 April 2024Gold price in 2024: geopolitical tensions and rate-cut expectations keep XAU/USD supported
Investors are keeping a close eye on gold as the conflict in the Middle East escalates with a possibility of a full-scale regional war in the area.
07:56, 17 April 2024US Earnings Season : JP Morgan, Citigroup, Wells Fargo
The first major US banks report quarterly earnings on Friday, April 12th, 2024. We preview what to expect from JP Morgan, Citigroup, and Wells Fargo's quarterly numbers.
16:03, 11 April 2024Reserve Bank of New Zealand Preview: Rates expected to remain on hold as inflation fight continues
The Reserve Bank of New Zealand (RBNZ) meets on Wednesday, April 10, 2024. We preview what to expect from the meeting and its possible impact on the NZD/USD.
09:22, 11 April 2024US CPI Preview: US inflation expected to grind lower amid fears about sticky prices
US CPI data is released on Wednesday, 10 April. We preview what to expect from the data, how it could influence US Federal Reserve policy, and analyse the NASDAQ (US Tech 100).
15:11, 9 April 2024How escalating geopolitical tensions are impacting oil markets
The bullish momentum in oil prices remains strong as escalating geopolitical tensions raise concerns about supply.
13:34, 4 April 2024People also watch
Still looking for a broker you can trust?
Join the 610,000+ traders worldwide that chose to trade with Capital.com